Inhibition of Cdk Activity
Allosteric Proteins-ATCase
Combination Therapies and Personalized Medicine
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Dec 20, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Abigail R Bland1, Nensi Shrestha1, Rhonda J Rosengren1
1Department of Pharmacology & Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Crizotinib, a lung cancer drug, does not inhibit cytochrome P450 3A (CYP3A) activity in vivo, contrary to in vitro findings. This study found no alteration in CYP3A activity or expression in mice treated with crizotinib.
Area of Science:
Background: